new_0222_0483|IMPL|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0483|IMPL|1|Impel NeuroPharma Inc Total Current Assets (Quarterly) (USD)|Impel NeuroPharma Inc Cash and Short Term Investments (Quarterly) (USD)|Impel NeuroPharma Inc Inventories (Quarterly) (USD)|Impel NeuroPharma Inc Net PP&E (Quarterly) (USD)|Impel NeuroPharma Inc Goodwill and Intangibles (Quarterly) (USD)|Impel NeuroPharma Inc Total Liabilities (Quarterly) (USD)|Impel NeuroPharma Inc Total Current Liabilities (Quarterly) (USD)|Impel NeuroPharma Inc Total Long Term Liabilities (Quarterly) (USD)|Impel NeuroPharma Inc Total Deposits (Quarterly) (USD)|Impel NeuroPharma Inc Book Value (Quarterly) (USD)|Impel NeuroPharma Inc Retained Earnings (Quarterly) (USD)|Impel NeuroPharma Inc Treasury Stock (Quarterly) (USD)|Impel NeuroPharma Inc EV to Revenues|Impel NeuroPharma Inc EV to Earnings|Impel NeuroPharma Inc EV to Free Cash Flow|Impel NeuroPharma Inc EV to Assets (Quarterly)|Impel NeuroPharma Inc PS Ratio|Impel NeuroPharma Inc PE Ratio|Impel NeuroPharma Inc Price to Book Value|Impel NeuroPharma Inc PEG Ratio|Impel NeuroPharma Inc Debt to Equity Ratio|Impel NeuroPharma Inc Dividend Yield|Impel NeuroPharma Inc Shareholder Yield (TTM)|Impel NeuroPharma Inc Percent of Shares Outstanding Short|Impel NeuroPharma Inc Total Receivables (Quarterly) (USD)|Impel NeuroPharma Inc Total Payables (Quarterly) (USD)|Impel NeuroPharma Inc Total Capital Stock (Quarterly) (USD)|Impel NeuroPharma Inc Return on Invested Capital|Impel NeuroPharma Inc Quality Ratio Score|Impel NeuroPharma Inc Momentum Score|Impel NeuroPharma Inc Beta (1Y)|Impel NeuroPharma Inc Sustainable Growth Rate (TTM)|Impel NeuroPharma Inc Institutional Investor Ownership Percentage|Impel NeuroPharma Inc Average Diluted Shares Outstanding (Quarterly)|Impel NeuroPharma Inc Total Employees (Annual)|Impel NeuroPharma Inc EPS Diluted (Quarterly) (USD)|Impel NeuroPharma Inc SG&A Expense (Quarterly) (USD)|Impel NeuroPharma Inc Shares Outstanding|Impel NeuroPharma Inc Repurchase of Capital Stock (Quarterly) (USD)|Impel NeuroPharma Inc Ordinary Shares Number (Quarterly)|Impel NeuroPharma Inc Payout Ratio|Impel NeuroPharma Inc Quick Ratio (Quarterly)|Impel NeuroPharma Inc Normalized Diluted EPS (Quarterly) (USD)|Impel NeuroPharma Inc Stock Buybacks (Quarterly) (USD)|Impel NeuroPharma Inc Effective Tax Rate (TTM)|Impel NeuroPharma Inc Return on Equity|Impel NeuroPharma Inc Net Income (TTM) (USD)|Impel NeuroPharma Inc Revenue (TTM) (USD)|Impel NeuroPharma Inc Dividend Per Share (Quarterly) (USD)|Impel NeuroPharma Inc Revenue (Quarterly) (USD)|Impel NeuroPharma Inc Gross Profit (Quarterly) (USD)|Impel NeuroPharma Inc Pre-Tax Income (Quarterly) (USD)|Impel NeuroPharma Inc Net Income (Quarterly) (USD)|Impel NeuroPharma Inc Net Interest Income (Quarterly) (USD)|Impel NeuroPharma Inc Price (USD)|Impel NeuroPharma Inc Total Return Price (USD)|Impel NeuroPharma Inc Enterprise Value (USD)|Impel NeuroPharma Inc 30-Day Average Daily Volume|Impel NeuroPharma Inc 1 Year Price Returns (Daily)|Impel NeuroPharma Inc Short Interest|Impel NeuroPharma Inc PE Ratio (Forward)|Impel NeuroPharma Inc PE Ratio (Forward 1y)|Impel NeuroPharma Inc PS Ratio (Forward)|Impel NeuroPharma Inc PS Ratio (Forward 1y)|Impel NeuroPharma Inc Quarterly EPS Estimates (USD)|Impel NeuroPharma Inc Quarterly Revenue Estimates (USD)|Impel NeuroPharma Inc Quarterly EPS Surprise|Impel NeuroPharma Inc Quarterly Revenue Surprise|Impel NeuroPharma Inc Quarterly Actual EPS (USD)|Impel NeuroPharma Inc Quarterly Actual Revenue (USD)|Impel NeuroPharma Inc Revenue Estimates for Current Fiscal Year (USD)|Impel NeuroPharma Inc Revenue Estimates for Next Fiscal Year (USD)|Impel NeuroPharma Inc Price Target (USD)|Impel NeuroPharma Inc Consensus Recommendation|Impel NeuroPharma Inc Price Target Num Estimates|Impel NeuroPharma Inc EPS Estimates for Current Fiscal Year (USD)|Impel NeuroPharma Inc EPS Estimates for Next Fiscal Year (USD)|Impel NeuroPharma Inc Research and Development Expense (Quarterly) (USD)|Impel NeuroPharma Inc Reconciled Depreciation (Quarterly) (USD)|Impel NeuroPharma Inc Non-Operating Interest Expense (Quarterly) (USD)|Impel NeuroPharma Inc Land and Improvements (Quarterly) (USD)|Impel NeuroPharma Inc Buildings and Improvements (Quarterly) (USD)|Impel NeuroPharma Inc Other Properties (Quarterly) (USD)|Impel NeuroPharma Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0483|IMPL|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0483|IMPL|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0483|IMPL|5|91|91||91||91|91|91||91|91||||1.44019138756||||1.43827160494|||1.44019138756||15.3333333333|91|91|91||||||30.6666666667|91.3333333333|90|91.3333333333|91.3333333333|25.625||91|||91.3333333333|91.4|91||91||||91.25|91.3333333333|91.3333333333|91.25|1.44019138756|1.44019138756|1.44019138756|1.43888888889||15.3333333333|||1.44117647059|1.44117647059|91.6666666667|91.4285714286||||91.5|16.5454545455|18.2|24.5|17.5|24.5|60.3333333333|60.3333333333|91.3333333333|91.3333333333|||||||
new_0222_0483|IMPL|6|3|3||3||3|3|3||3|3||||209||||162|||209||18|3|3|3||||||9|6|1|6|6|8||3|||6|5|3||3||||4|6|6|4|209|209|209|180||18|||34|34|3|7||||2|11|10|10|14|10|3|3|6|6|||||||
new_0222_0483|IMPL|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0483|IMPL|202003||||||||||||||||||||||||||||||||||13.1389||-0.7525|3.452||||||-0.7428|||||||||-9.758|-9.759|0.033||||||||||||||||||||||||6.354|0.219|||||||
new_0222_0483|IMPL|202006||||||||||||||||||||||||||||||||||13.1389||-0.9932|6.127||||||-0.9835|||||||||-12.923|-12.922|||||||||||||||||||||||||6.832|0.257|||||||
new_0222_0483|IMPL|202009||||||||||||||||||||||||||||||||||13.1389||-0.702|2.866||||||-0.6921|||||||||-9.092|-9.093|||||||||||||||||||||||||6.133|0.338|||||||
new_0222_0483|IMPL|202012|8.172|7.095||3.7||145.559|10.526|135.033||-133.5|-138.262||||||||||||||0.229|4.314||||||||13.1389|61|-1.0263|5.809|||19.4148|||-1.0674||-0.0022||-45.798|||||-14.024|-14.024|||||||||||||||||||||||||7.761|0.263||||4.613|0.1||
new_0222_0483|IMPL|202103|6.259|4.467||3.512||155.891|13.394|142.497||-144.409|-149.553||||-7.7192|||||||||0.2479|0.229|6.425|||||||15.109|19.4148|64|-0.5882|5.771|19.4148||19.4148|||-0.5816||||-47.33|||||-11.291|-11.291|-0.298|15.2|15.2|307.634|||48133|||||||||||1.353|33.6593|29.3333|1|3|-3.7|-2.85|4.098|0.25||||||11.17|
new_0222_0483|IMPL|202106|65.567|60.948||3.408||17.864|9.007|8.857||51.298|-165.035||||-2.5642||||3.3591|||||2.98|0.025|5.461|0.019|||||||14.1197||-1.1|8.862|19.4709||19.4709|||-1.1|-71.997|-0.002||-49.89|||||-15.482|-15.482||8.85|8.85|120.2265|94805.6||580224|||||||||||2.0295|33.6593|30.6667|1|3|||6.076|0.243||||||14.06|18.99
new_0222_0483|IMPL|202109|118.203|111.289|1.548|3.278||45.595|16.31|29.285||75.886|-190.056||||-3.6359|1.6347|||3.6976||0.3859|||4.0809|1.274|8.7|0.023||||||96.3848|20.151||-1.24|16.338|23.0373||23.0373||6.9015|-1.24|-48.316|||-65.818|||0.091|-0.159|-25.021|-25.021||12.18|12.18|198.5903|1228535.7333||940118||||||||||0.091|1.7683|50.354|48|1|3|-4|-3.4|5.929|0.282||||||10.69|9.24
new_0222_0483|IMPL|202112|||||||||||||||-2.1389||||2.6201|||||2.0529|||||||||96.1454||||||||||||||||||||||8.63|8.63|116.826|171196.2667||472982|||5.3069|1.7739||1.6567|||||||48.3333|1|3||||||||||8.7|7.53
new_0222_0483|IMPL|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.95|3.7||||||||||||||||||||
new_0222_0483|IMPL|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.87|7.2833||||||||||||||||||||
new_0222_0483|IMPL|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.73|11.5167||||||||||||||||||||
new_0222_0483|IMPL|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.57|14.9667||||||||||||||||||||